PPT
... • Transgenic Animals (hPXR) – 5X increase in mRNA & activity • Clinical Studies (DDI) – 65-98% decreases in AUC ...
... • Transgenic Animals (hPXR) – 5X increase in mRNA & activity • Clinical Studies (DDI) – 65-98% decreases in AUC ...
Lecture 1 Dr.fatima Principles in the management of poisoned
... acetaminophen poisoning, but recent studies reported no significant differences in N-acetyl cysteine serum concentration, peak concentration or half-life when given with activated charcoal. Cathartics Saline cathartics are desired to remove toxic substances from GIT. As contact between the poison an ...
... acetaminophen poisoning, but recent studies reported no significant differences in N-acetyl cysteine serum concentration, peak concentration or half-life when given with activated charcoal. Cathartics Saline cathartics are desired to remove toxic substances from GIT. As contact between the poison an ...
DIM Detox - Pure Encapsulations
... detoxification through the glucuronidation pathway. Lignans such as 7-hydroxymatairesinol (HMR) are converted in the body to enterolactone. Research indicates that dietary intake of lignans and healthy serum enterolactone levels provide support for cell, heart, breast, bone and cognitive health. Sil ...
... detoxification through the glucuronidation pathway. Lignans such as 7-hydroxymatairesinol (HMR) are converted in the body to enterolactone. Research indicates that dietary intake of lignans and healthy serum enterolactone levels provide support for cell, heart, breast, bone and cognitive health. Sil ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... predominantly averted. Orally administered therapeutics has the potentialities to increase treatment regimen, upregulate patient satisfaction and adherence; and consequently improve efficacy. Furthermore, small molecules generally possess short half lives but longer shelf lives when compared to larg ...
... predominantly averted. Orally administered therapeutics has the potentialities to increase treatment regimen, upregulate patient satisfaction and adherence; and consequently improve efficacy. Furthermore, small molecules generally possess short half lives but longer shelf lives when compared to larg ...
Drug metabolism and pharmacogenetics
... than is regenerated and Nacetylbenzoiminoquinone (toxic metabolite that reacts with proteins) accumulates •N-acetylcysteine is administered w/I 8-16 hours to protect from hepatotoxicity ...
... than is regenerated and Nacetylbenzoiminoquinone (toxic metabolite that reacts with proteins) accumulates •N-acetylcysteine is administered w/I 8-16 hours to protect from hepatotoxicity ...
ESTIMATION OF THE ANTI-ULCER PROPERTIES OF KETOTIFEN IN ASPIRIN AND... STRESS INDUCED ALBINO RATS
... hemorrhagic area per stomach, significantly. It also increased mean survival time. However, maximum effect was seen in 2mg/kg dose. Ranitidine 10 mg/kg significantly reduced the ulcer index, number of ulcer and has hemorrhagic area per stomach on stress induced gastric ulcer (Table 2). ...
... hemorrhagic area per stomach, significantly. It also increased mean survival time. However, maximum effect was seen in 2mg/kg dose. Ranitidine 10 mg/kg significantly reduced the ulcer index, number of ulcer and has hemorrhagic area per stomach on stress induced gastric ulcer (Table 2). ...
Cimetidine - Clemson University
... • Replacement of the furan ring in Zantac by a thiazole group gives the drug Axid. • Axid is 5 to 18 times more potent than cimetidine. • In Pepcid, the N-methyl-2-nitro-1,1ethenediamine group of axid is replaced by the aminosulfonylimidamide function, and the dimethylaminomethyl group is replaced ...
... • Replacement of the furan ring in Zantac by a thiazole group gives the drug Axid. • Axid is 5 to 18 times more potent than cimetidine. • In Pepcid, the N-methyl-2-nitro-1,1ethenediamine group of axid is replaced by the aminosulfonylimidamide function, and the dimethylaminomethyl group is replaced ...
Exam Sample-1
... 30- In drug design we may increase the susceptibility of drug to metabolic reaction in case of: a) drug toxicity b) lingering side effects c) drug tolerance d) short drug half-life e) both a) and b) 31- Which of the following is incorrect: a) valium is the prodrug of nordiazepam b) salicylic acid is ...
... 30- In drug design we may increase the susceptibility of drug to metabolic reaction in case of: a) drug toxicity b) lingering side effects c) drug tolerance d) short drug half-life e) both a) and b) 31- Which of the following is incorrect: a) valium is the prodrug of nordiazepam b) salicylic acid is ...
proper usage of drugs, chemicals and feed additives in food animals
... Shock may be observed following intravenous administration, especially where highly concentrated materials are involved. To minimize this occurrence, it is recommended that LIQUAMYCIN® LA-200 ® be administered slowly by this route. Shortly after injection, treated animals may have transient hemoglob ...
... Shock may be observed following intravenous administration, especially where highly concentrated materials are involved. To minimize this occurrence, it is recommended that LIQUAMYCIN® LA-200 ® be administered slowly by this route. Shortly after injection, treated animals may have transient hemoglob ...
HISTAMINE AND HISTAMINE ANTAGONISTS
... Effects on Human Heart (ref: G & G) • Histamine affects both cardiac contractility and electrical events directly. It increases the force of contraction of both atrial and ventricular muscle by promoting the influx of Ca2+, and • it speeds heart rate by hastening diastolic depolarization in the sin ...
... Effects on Human Heart (ref: G & G) • Histamine affects both cardiac contractility and electrical events directly. It increases the force of contraction of both atrial and ventricular muscle by promoting the influx of Ca2+, and • it speeds heart rate by hastening diastolic depolarization in the sin ...
TAZAC®
... Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. Antisecretory Activity-1. Effects on Acid Secretion: Nizatidine significantly inhibits basal and nocturnal gastricacid secretion for up to 12 hours. Nizatid ...
... Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. Antisecretory Activity-1. Effects on Acid Secretion: Nizatidine significantly inhibits basal and nocturnal gastricacid secretion for up to 12 hours. Nizatid ...
Time-Release Lipoic Acid: More Marketing than Data
... fructosamine levels in diabetic patients taking CRLA, absent from the abstract and conclusion were the mention that no changes were seen in fasting blood glucose, HbA1c or serum triglycerides- other important markers for improved glucose control. The authors state (in their discussion) that the reas ...
... fructosamine levels in diabetic patients taking CRLA, absent from the abstract and conclusion were the mention that no changes were seen in fasting blood glucose, HbA1c or serum triglycerides- other important markers for improved glucose control. The authors state (in their discussion) that the reas ...
Metabolic Transformations of Xenobiotics
... • Biotransformation is the process by which a drug is chemically altered by the body. • The liver is the principal, but not the only, site of drug biotransformation. The liver has enzymes that facilitate chemical reactions such as oxidation, reduction, and hydrolysis of drugs (phase I). It has other ...
... • Biotransformation is the process by which a drug is chemically altered by the body. • The liver is the principal, but not the only, site of drug biotransformation. The liver has enzymes that facilitate chemical reactions such as oxidation, reduction, and hydrolysis of drugs (phase I). It has other ...
INTRODUCTION TO PHARMACOLOGY
... the drug may be produced by different pharmaceutical companies under new product (trade) names but at the basis of original active substance (similar quantity, route of administration etc.) ...
... the drug may be produced by different pharmaceutical companies under new product (trade) names but at the basis of original active substance (similar quantity, route of administration etc.) ...
DRS
... L-Glutamine, well–recognized for gut and immune support, has also been espoused to reduce carbohydrate cravings and support alcohol withdrawal, although the mechanism of action for these benefits is not known.*[7,8] Chromium, as chromium picolinate is widely used to optimize insulin function; thereb ...
... L-Glutamine, well–recognized for gut and immune support, has also been espoused to reduce carbohydrate cravings and support alcohol withdrawal, although the mechanism of action for these benefits is not known.*[7,8] Chromium, as chromium picolinate is widely used to optimize insulin function; thereb ...
drug induced injury of the gi tract
... inflammation and eventually ulceration. Endoscopically, lesions present as discrete “punched out” ulcers with relatively little damage to adjacent mucosa. Histologically there is neutrophil infiltration, erosions or deep ulcers. Occasionally polarizable crystalline pill remnants can be identified. T ...
... inflammation and eventually ulceration. Endoscopically, lesions present as discrete “punched out” ulcers with relatively little damage to adjacent mucosa. Histologically there is neutrophil infiltration, erosions or deep ulcers. Occasionally polarizable crystalline pill remnants can be identified. T ...
Acid Base
... Look up the two amphiprotic ions on the left side of the acid chart. The higher one is the stronger acid and will be the acid and donate a proton to the base. ...
... Look up the two amphiprotic ions on the left side of the acid chart. The higher one is the stronger acid and will be the acid and donate a proton to the base. ...
INTRODUCTION TO PHARMACOLOGY
... the drug may be produced by different pharmaceutical companies under new product (trade) names but at the basis of original active substance (similar quantity, route of administration etc.) ...
... the drug may be produced by different pharmaceutical companies under new product (trade) names but at the basis of original active substance (similar quantity, route of administration etc.) ...
Synthesis and Characterization of Pharmaceutical salt of
... (BCS) (Amidon, 1995) Prulifloxacin is a class II drug i.e. those having low solubility and low permeability. Currently Prulifloxacin is marketed as a 600 mg oral dosage form under the brand name percin. In order to change the physio chemical properties especially to enhance its solubility thereby bi ...
... (BCS) (Amidon, 1995) Prulifloxacin is a class II drug i.e. those having low solubility and low permeability. Currently Prulifloxacin is marketed as a 600 mg oral dosage form under the brand name percin. In order to change the physio chemical properties especially to enhance its solubility thereby bi ...
Medications Requiring Prior Authorization for Medical
... There may be additional drugs subject to prior authorization or other plan design restrictions. Please consult your plan for further information. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. This is not an a ...
... There may be additional drugs subject to prior authorization or other plan design restrictions. Please consult your plan for further information. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. This is not an a ...
Gout druges (2012).
... uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or sulfinpyrazone 3.inhibiting leukocyte entry into the affec ...
... uric acid level below the saturation point (<6 mg/dL), thus preventing the deposition of urate crystals. This can be accomplished by: 1.interfering with uric acid synthesis with allopurinol 2.increasing uric acid excretion with probenecid or sulfinpyrazone 3.inhibiting leukocyte entry into the affec ...
RANIMED® Syrup Dear patient, Please read the
... Each 5 mL of RANIMED 5 mg/mL syrup contain 25 mg ranitidine (as ranitidine HCl). Each 5 mL of RANIMED 10 mg/mL syrup contain 50 mg ranitidine (as ranitidine HCl). RANIMED syrup is for oral use. Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2receptors, ...
... Each 5 mL of RANIMED 5 mg/mL syrup contain 25 mg ranitidine (as ranitidine HCl). Each 5 mL of RANIMED 10 mg/mL syrup contain 50 mg ranitidine (as ranitidine HCl). RANIMED syrup is for oral use. Ranitidine is a competitive, reversible inhibitor of the action of histamine at the histamine H2receptors, ...
Discovery and development of proton pump inhibitors
Proton pump inhibitors (PPIs) block the gastric hydrogen potassium ATPase (H+,K+-ATPase) and inhibit gastric acid secretion. These drugs have emerged as the treatment of choice for acid-related diseases, including gastroesophageal reflux disease (GERD) and peptic ulcer disease.PPIs also can bind to other types of proton pumps such as those that occur in cancer cells and are finding applications in the reduction of cancer cell acid efflux and reduction of chemotherapy drug resistance.